Michael Henderson, M.D.
Principal executive officer pay for Michael Henderson, M.D., by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Apogee Therapeutics, Inc. (APGE) FY2023–FY2025
Beat peersTSR 170% vs peer group 33% over FY2023–FY2025
Pay cut while stock roseCAP $35,328,071→$15,951,124 while $100 invested went $132.00→$356.00 (FY2023–FY2025)
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2023 | $8.7M | $35.3M |
| FY2024 | $13.2M | $35.1M |
| FY2025 | $1.3M | $16.0M |
The company's "$100 invested" index ran $132.00 at FY2023 → $356.00 by FY2025 — an annualized return of 64.2%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 64.2%/yr at APGE ( FY2023–FY2025). See the CEO track-record ranking for context.